Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 99 results for melanoma

  1. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over (NG36)

    This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 and over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. It aims to reduce variation in practice and improve survival.

  2. Technology appraisal and highly specialised technologies appeals

    Technology appraisal and Highly specialised technologies appeals

  3. Medical technologies guidance

    Our medical technologies guidance evaluates new, innovative medical devices and diagnostics.

  4. Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

    Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.

  5. What proportion of people with melanoma who are referred into secondary care under the 2 week wait rule, have equivocal moles that are excised and have equivocal moles that are monitored?

    Recommendation ID DG19/2 Question What proportion of people with melanoma who are referred into secondary care under the 2 week wait...

  6. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development [GID-TA11458] Expected publication date: TBC

  7. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued [GID-IP1041]

  8. What is the impact of using the VivaScope 1500 and 3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care in England, particularly on excision rates, diagnostic accuracy, health related quality of life and associated NHS costs?

    the VivaScope 1500 and 3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care...

  9. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

  10. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    analysis of melanoma tissue samples. Full details of the evidence and the committee's discussion are in evidence review A: genetic...

  11. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued [GID-TA10330]

  12. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued [GID-TAG401]

  13. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

  14. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued [GID-TA10686]

  15. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued [GID-TA10836]